JonathanEliotBenjaminMD
Oncology • South San Francisco, CAVice President for Clinical Research Atreca
Dr. Benjamin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Atreca, Inc.
450 East Jamie Court
South San Francisco, CA 94080Phone+1 650-453-5275- Is this information wrong?
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 2001 - 2004
New York University School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2003 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
- Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2010 Nov 01
- Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsDonor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms.Rupa Narayan, Jonathan Benjamin, Omid Shah, Lu Tian, Keri Tate, Randall Armstrong, Bryan J. Xie, Robert Lowsky, Ginna G. Laport, Robert S. Negrin, Everett Meyer> ;Biology of Blood and Marrow Transplantation. 2019 Jul 1
- 477 citationsBlinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemiaNicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, H. Diedrich, Max S. Topp, Monika Brüggemann, Heinz-August Horst...> ;Blood. 2018 Apr 5
- 18 citationsBlinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.Max S. Topp, M Stelljes, Gerhard Zugmaier, Phillip Barnette, Leonard T. Heffner, Tanya M. Trippett, Johannes Duell, Ralf C. Bargou, Chris Holland, Jonathan Benjamin, M...> ;Leukemia. 2018 Feb 1
- Join now to see all
Press Mentions
13 Discoveries in the Last Year Have Fundamentally Altered Our Understanding of Human HistoryDecember 11th, 2020
Professional Memberships
- Member
- Member
- American Society for Blood and Marrow TransplantationMember
Hospital Affiliations
- Saint Mary's Regional Medical CenterReno, Nevada
Industry Relationships
- Vice President Clinical Research, Atreca, Inc2017 - Present
- Medical Director, Amgen2014 - 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
